Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Gastrointestinal Stromal Tumors 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Myeloproliferative Disorders 1Melanoma 1Digestive System Neoplasms 1Congenital Bone Marrow Failure Syndromes 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Cyclophosphamide 8asciminib 7fludarabine phosphate 6fludarabine 5Mycophenolic Acid 5nilotinib 3Whole-Body Irradiation 3Thiotepa 3Tacrolimus 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Cyclosporine 3venetoclax 2Sirolimus 2Melphalan 2Filgrastim 2Dasatinib 2Cyclosporins 2treosulfan 1thymoglobulin 1selinexor 1ruxolitinib 1ponatinib 1plerixafor 1olverembatinib 1midostaurin 1merphos 1gilteritinib 1bosutinib 1blinatumomab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Imatinib Mesylate × 30 days × Clear all
NCT00070499 2026-05-29

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
406 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05413915 2026-05-29

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Sir Mortimer B. Davis - Jewish General Hospital

Phase 3 Terminated
8 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04877522 2026-05-11

Asciminib Roll-over Study

Novartis

Phase 4 Recruiting
347 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡